🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525200-99-00
Authorised Phase I

Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare

2026-525200-99-00 · tracked via the Priya Life Science EU tracker
Sponsor
Dianosic
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
21/05/2026
Enrollment target
25
Sites
Netherlands

Condition studied

Chronic allergic rhinitis

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525200-99-00 on CTIS ↗ ← All trials in the EU